WallStreetZenWallStreetZen

NASDAQ: GENE
Genetic Technologies Ltd Stock

$2.89+0.08 (+2.85%)
Updated Mar 28, 2024
GENE Price
$2.89
Fair Value Price
N/A
Market Cap
$667.11k
52 Week Low
$1.80
52 Week High
$120.00
P/E
-0.97x
P/B
0.21x
P/S
0.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.55M
Earnings
-$8.67M
Gross Margin
53.5%
Operating Margin
-149.85%
Profit Margin
-150%
Debt to Equity
0.76
Operating Cash Flow
-$5M
Beta
0.68
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GENE Overview

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GENE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GENE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GENE is good value based on its book value relative to its share price (0.21x), compared to the US Diagnostics & Research industry average (4.38x)
P/B vs Industry Valuation
GENE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GENE due diligence checks available for Premium users.

Be the first to know about important GENE news, forecast changes, insider trades & much more!

GENE News

Valuation

GENE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.97x
Industry
37.37x
Market
44.51x

GENE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.21x
Industry
4.38x
GENE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GENE's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
GENE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GENE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$5.8M
Liabilities
$2.5M
Debt to equity
0.76
GENE's short-term assets ($3.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GENE's short-term assets ($3.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GENE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
GENE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GENE vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
GENE$667.11k+2.85%-0.97x0.21x
ISPC$2.11M-7.57%-0.19x0.22x
NDRA$6.40M-29.27%-0.37x1.13x
APDN$6.96M-4.21%-0.75x1.64x
MDXH$7.00M+5.28%-0.16x0.97x

Genetic Technologies Stock FAQ

What is Genetic Technologies's quote symbol?

(NASDAQ: GENE) Genetic Technologies trades on the NASDAQ under the ticker symbol GENE. Genetic Technologies stock quotes can also be displayed as NASDAQ: GENE.

If you're new to stock investing, here's how to buy Genetic Technologies stock.

What is the 52 week high and low for Genetic Technologies (NASDAQ: GENE)?

(NASDAQ: GENE) Genetic Technologies's 52-week high was $120.00, and its 52-week low was $1.80. It is currently -97.59% from its 52-week high and 60.56% from its 52-week low.

How much is Genetic Technologies stock worth today?

(NASDAQ: GENE) Genetic Technologies currently has 115,417,246 outstanding shares. With Genetic Technologies stock trading at $2.89 per share, the total value of Genetic Technologies stock (market capitalization) is $667.11k.

Genetic Technologies stock was originally listed at a price of $24,000.00 in Sep 6, 2005. If you had invested in Genetic Technologies stock at $24,000.00, your return over the last 18 years would have been -99.99%, for an annualized return of -39.43% (not including any dividends or dividend reinvestments).

How much is Genetic Technologies's stock price per share?

(NASDAQ: GENE) Genetic Technologies stock price per share is $2.89 today (as of Mar 28, 2024).

What is Genetic Technologies's Market Cap?

(NASDAQ: GENE) Genetic Technologies's market cap is $667.11k, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Genetic Technologies's market cap is calculated by multiplying GENE's current stock price of $2.89 by GENE's total outstanding shares of 115,417,246.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.